Advances in cancer biology and sequencing technology have enabled the selection of
targeted and more effective treatments for individual patients with various types of solid …

Gastric cancer is one of the leading causes of cancer-related death worldwide. Many
patients have inoperable disease at diagnosis or have recurrent disease after resection with …

Gastric cancer (GC) is one of the leading causes of cancer-related deaths and shows high
levels of heterogeneity. The development of a specific prognostic model is important if we …

Receptor tyrosine kinases (RTKs) play an important role in a variety of cellular processes
including growth, motility, differentiation, and metabolism. As such, dysregulation of RTK …

Abstract Background In the Trastuzumab for GAstric cancer (ToGA) study, trastuzumab plus
chemotherapy improved median overall survival by 2.7 months in patients with human …

Purpose In Asian countries, paclitaxel once per week is used as second-line treatment in
advanced gastric cancer, including human epidermal growth factor receptor 2 (HER2) …

Human epidermal growth factor receptor 2 (HER2) overexpression is increasingly
recognized as a frequent molecular abnormality in gastric and gastroesophageal cancer …

Overexpression of human epidermal growth factor receptor type 2 (HER2) in breast cancer
is associated with decreased overall survival. Trastuzumab, a humanized monoclonal …

Gastric cancer is the second leading cause of cancer mortality in the world and its
management, especially in advanced stages, has evolved relatively little. In particular, no …

Gastric cancer is one of the most common malignancies worldwide. During the last 50 years,
the histological classification of gastric carcinoma has been largely based on Lauren's …